Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Annelise Capossela/Axios

A CDC advisory committee will meet Wednesday to evaluate the risk of heart inflammation in teens who get the Pfizer or Moderna vaccines.

Why it matters: Cases of heart inflammation are rare, but they've raised concerns among some experts and scientists — including some whose job it is to sift through those risks and recommend whether to authorize the vaccines for children younger than 12.

What they're saying: “Myocarditis is something that needs to be looked at closely because we’re likely seeing the tip of the iceberg," Michael Kurilla, a member of an FDA Advisory Committee on vaccines, said earlier this month.

Yes, but: Out of 310 million vaccine doses administered, there have been 323 confirmed cases of myocarditis or pericarditis as of June 14, according to the CDC.

  • The cases have been primarily from teens and men age 30 and younger. Symptoms were usually mild, and the overwhelming majority of patients who were hospitalized with the condition — 81% — made a full recovery.
  • Unvaccinated children and young adults are also at higher risk of getting heart inflammation and related conditions if they contract COVID-19, experts say.

The bottom line: Many observers say they don't expect the advisory committee to recommend against vaccination for teens or young adults.

  • "It may well be in the end that we stay where we are," incoming American Heart Association president Donald Lloyd-Jones told Axios.
  • The panel "will do what they did for the J&J vaccine, which is to put it in context and allow the listener to understand the concept of relative risk — that a choice not to get these vaccines is not a risk-free choice," said Paul Offit, a member of FDA's vaccine advisory panel.

Go deeper

Updated 15 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Vaccines: Los Angeles County to require vaccination proof at indoor bars — France suspends 3,000 unvaccinated health workers without pay — Moderna suggests booster shots, citing clinical data.
  2. Health: 1 in 500 Americans has died — Cases are falling, but deaths are rising — Study: Gaps in data on Native Hawaiians, Pacific Islanders alarming amid COVID.
  3. Politics: Gottlieb says CDC hampered U.S. response — 26 states have limited state or local officials' public health powers — Axios-Ipsos poll: 60% of voters back Biden vaccine mandates.
  4. Education: Denver looks to students to close Latino vaccination gap — Federal judge temporarily blocks Iowa's ban on mask mandates in schools — Massachusetts activates National Guard to help with school transportation.
  5. Variant tracker: Where different strains are spreading.
Sep 15, 2021 - Science

Moderna suggests booster shots, citing clinical data

A box of the Moderna COVID-19 vaccine in Indonesia. Photo: Algi Febri Sugita/SOPA Images/LightRocket via Getty Images

Moderna vaccine's efficacy declines a year after it's administered, compared to protection seen in recently inoculated individuals, the vaccine maker announced Wednesday.

Driving the news: Moderna made its case for supporting booster shots, citing clinical trial data that demonstrate breakthrough infections are less common among participants approximately eight months after receiving the first dose compared to approximately 13 months.

Sep 15, 2021 - World

EU pledges 200 million vaccine doses to Africa, low-income nations

Photo: Patrick Meinhardt/AFP via Getty Images

European Commission President Ursula von der Leyen said Wednesday that the bloc would donate an additional 200 million coronavirus vaccine doses to Africa and low-income nations, AP reports.

Why it matters: The new donation, slated to be delivered by the middle of next year, comes as confirmed cases of the coronavirus have reached 225 million globally.